Visceral Fat vs Subcutaneous Fat: A Surgeon's Mechanism Guide

Dr. Fitz Nutrition — Metabolic Health & Fitness

Visceral fat surrounds the abdominal organs and drains directly into the liver via the portal vein. Subcutaneous fat sits under the skin and drains into systemic circulation. Two anatomically distinct tissues with very different metabolic consequences.

Michael Fitzmaurice, M.D.

Peripheral Nerve Surgeon & Metabolic Health Educator

"As a surgeon, I think anatomically. The most important fact about visceral fat is not that it sits near your organs. It is that its venous drainage runs straight to your liver before anything dilutes it. That single anatomical detail explains most of what makes this tissue dangerous, and most of what makes generic 'belly fat' advice miss the point."

Most articles about visceral fat get the location right and the physiology wrong. They tell you it sits around your organs, that subcutaneous fat sits under your skin, and that one is more dangerous than the other. All true. None of it explains why.

The honest answer involves anatomy, not just adjectives. Visceral and subcutaneous fat differ in cell size, mitochondrial density, vascular supply, sympathetic innervation, hormone secretion, and most importantly, where their venous blood drains. Visceral fat empties directly into your liver. Subcutaneous fat does not. That single anatomical fact, first articulated by Per Björntorp in 1990 and refined across thirty-five years of clinical research, explains why a man with a 40-inch waist and normal labs is still at meaningful cardiometabolic risk, and why a woman carrying weight in her hips and thighs may have far better insulin sensitivity than her BMI predicts.

This is the deep version of that story. We will cover what these tissues actually are at the cellular level, why visceral fat is described as metabolically active and what that phrase really means, how to measure it accurately (and which methods are mostly marketing), what reduces it, and the recent literature that complicates the simple "visceral bad, subcutaneous good" narrative. The evidence has gotten more interesting in the past three years.

What You'll Learn About Visceral Fat vs Subcutaneous Fat

▸  Why visceral fat behaves like an endocrine organ and subcutaneous fat behaves like a buffer

▸  The portal vein anatomy that makes visceral fat uniquely harmful to the liver

▸  What the "6% of systemic fatty acids" finding actually means for the popular narrative

▸  How to measure visceral fat accurately and which scales are essentially guessing

▸  Why exercise reduces visceral fat at lower energy deficits than caloric restriction does

▸  Where the simple visceral-vs-subcutaneous binary breaks down (deep SAT, ectopic fat, normal-weight visceral obesity)

What Visceral and Subcutaneous Fat Actually Are

Adipose tissue is not a passive storage warehouse. It is an organ, in the same way the liver and kidneys are organs, with depot-specific biology that has been characterized at increasing resolution since the early 2000s. The two main categories most people care about are visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), and the differences between them go far beyond location. Understanding body fat distribution, how and where fat is stored in the body, is crucial, as it significantly influences metabolic health and disease risk.

Visceral fat

Visceral fat surrounds the organs in your abdominal cavity, specifically enveloping internal organs and abdominal organs such as the liver, intestines, and pancreas. Visceral fat is located deep within the abdomen, around these vital organs, and is distinct from subcutaneous fat that lies beneath the skin. Because of its proximity to vital organs, visceral fat is considered "active fat," meaning it is metabolically and hormonally active, influencing how the body functions and contributing to health risks such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. The two main subtypes are omental fat (the apron of tissue draped over your intestines) and mesenteric fat (the tissue inside the folds that hold your intestines in place). Both drain into the portal vein. This is the fat that contributes to a hard, distended abdomen, the "beer belly" phenotype, and what physicians often call central or android adiposity.

At the cellular level, visceral adipocytes have higher mitochondrial density and oxidative capacity than subcutaneous adipocytes, more robust sympathetic innervation, denser vascularization per unit mass, and a more inflammatory secretory profile. They are also less sensitive to insulin's anti-lipolytic effect, which means they release fatty acids more readily after meals than subcutaneous fat does.

Subcutaneous fat

Subcutaneous fat sits directly beneath the skin and above your muscle. It exists everywhere on your body, but the depots most studied for metabolic implications are the abdominal SAT (around your waist) and the gluteofemoral SAT (around your hips, buttocks, and thighs). Subcutaneous fat drains into your systemic venous circulation, which dilutes its secretory products throughout the body before they reach any single organ.

Functionally, gluteofemoral SAT acts as a metabolic buffer. It expands to accommodate caloric surplus, sequesters fatty acids away from ectopic deposition, and is associated with better metabolic health when present in higher proportions. Body shape, such as a "pear shape" (more fat stored in hips and thighs) versus an "apple shape" (more fat stored in the abdomen), reflects where your body tends to store fat, highlighting the difference between subcutaneous versus visceral fat. This is part of why hip-and-thigh fat distribution, classically described as a "pear shape," predicts lower cardiometabolic risk than abdominal-dominant distribution at the same BMI.

The Portal Vein: The Anatomical Reason Visceral Fat Is Different

This is the section most articles never write, and it is the one that actually matters. As a peripheral nerve surgeon, I think about drainage patterns constantly. They determine which infections become life-threatening, which tumors spread where, and which tissues expose downstream organs to whatever they release. The portal vein is the most consequential drainage system in human metabolism.

The portal pathway in three steps: visceral adipocytes release fatty acids and inflammatory cytokines, the portal vein delivers them undiluted to the liver, and hepatic insulin signaling deteriorates as a result. The mechanism is anatomical, not just hormonal.

Your gut, your pancreas, your spleen, and your visceral fat all drain their venous blood into the hepatic portal vein, which empties into the liver. This is why nutrients from your meals reach the liver first, before any other organ. It is also why anything visceral fat makes and releases, such as free fatty acids, glycerol, inflammatory cytokines, and adipokines, reaches the liver at concentrations far higher than those measured in your peripheral blood. There is no dilution. The liver gets the undiluted signal.

Subcutaneous fat drains into the systemic venous circulation, which empties into your right heart, then lungs, then back through arterial circulation to the rest of your body. By the time anything from subcutaneous fat reaches your liver, it has been diluted across roughly five liters of blood and distributed across every organ system.

This anatomical asymmetry is the foundation of what is called the portal hypothesis, first articulated by Per Björntorp in 1990 and refined extensively since. The hypothesis argues that visceral fat is mechanistically dangerous not because it is the largest source of circulating fatty acids (it is not), but because it delivers a concentrated bolus of lipotoxic and pro-inflammatory signals to the liver before any dilution occurs.

The "6% of fatty acids" finding most articles get wrong

Here is a counter-intuitive fact you will not see on most health blogs. Despite its high lipolytic rate, the amount of visceral fat present determines its contribution to systemic non-esterified fatty acids: visceral fat contributes only about 6% of systemic non-esterified fatty acids in lean individuals and about 13% in obesity. Roughly 70% of circulating fatty acids actually come from upper-body subcutaneous fat. So the lazy narrative that "visceral fat dumps fatty acids into your blood" is technically wrong at the level of total flux.

The portal hypothesis does not depend on visceral fat being the dominant systemic source. It depends on visceral fat being the dominant portal source, which it absolutely is. The liver sees fatty acids and cytokines from visceral depots at concentrations no other organ encounters. Combined with simultaneous portal delivery of IL-6 and TNF-α (inflammatory cytokines visceral fat secretes far more readily than subcutaneous fat), the result is a uniquely toxic exposure for hepatocytes that drives:

Hepatic lipid accumulation, when fatty acid influx outpaces β-oxidation and gets shunted into triglyceride synthesis and VLDL production. Increased gluconeogenesis, as portal fatty acids and glycerol upregulate G6Pase and PEPCK and drive fasting hyperglycemia. Hepatic insulin receptor downregulation, with reductions of roughly 50% reported in animal models of visceral obesity. Inflammatory amplification, as portal IL-6 and TNF-α activate NF-κB and STAT3 signaling and impair insulin signaling through IRS-1 serine phosphorylation. And eventually, the development of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD).

An important nuance from a 2009 PNAS paper by Fabbrini and colleagues: intrahepatic triglyceride content may actually be the more proximal mediator of metabolic disease, with visceral fat acting partly as a determinant of liver fat rather than independently causing insulin resistance through some other pathway. This refines the portal hypothesis without overturning it. Visceral fat is the upstream cause; liver fat is the downstream mediator. Both matter.

Why Visceral Fat Is "Metabolically Active"

"Metabolically active" is one of the most overused phrases in popular health content and one of the least often explained. It rests on three converging properties of visceral adipose tissue. Excess fat, especially excessive visceral fat, is associated with increased metabolic activity and significantly higher health risks, including metabolic syndrome, diabetes, and heart disease.

1. Higher stimulated lipolysis

Under basal conditions, visceral adipocytes have similar or even slightly lower lipolytic rates than subcutaneous adipocytes. The difference shows up when you stimulate them. When exposed to adrenergic agonists (the catecholamines released during exercise, fasting, and stress), visceral adipocytes respond with markedly higher percent-change lipolysis than subcutaneous cells. The molecular basis: lower α2-adrenergic receptor density (which would normally inhibit lipolysis), higher β3-adrenergic receptor function, and differential expression of perilipin-1 and CGI-58 on the lipid droplet surface.

In one foundational study comparing markedly obese to non-obese subjects, catecholamine-induced fatty acid mobilization from omental fat cells was 2-fold higher in the obese group, driven primarily by elevated β3-AR function in visceral adipocytes. Visceral fat is built to release fat under stress signaling. Subcutaneous fat is built to hold onto it.

2. Lower insulin sensitivity

Insulin's job at adipocytes is to suppress lipolysis and promote storage. It does this through PKB/Akt activation of phosphodiesterase 3B, which hydrolyzes cAMP and shuts off the lipolytic cascade. The anti-lipolytic potency of insulin is significantly lower in visceral adipocytes than in subcutaneous ones, partly due to lower insulin receptor density and partly due to greater inflammatory cytokine exposure that impairs IRS-1 signaling through serine phosphorylation. The result: even after a meal, when insulin should be quieting fatty acid release, visceral fat keeps releasing more fatty acids than subcutaneous fat does. The portal vein keeps delivering them to the liver.

3. Pro-inflammatory secretion

Visceral fat secretes substantially higher concentrations of IL-6, IL-8, MCP-1, and TNF-α than subcutaneous fat, and these depot differences amplify with obesity. Most of this inflammatory output comes not from the adipocytes themselves but from the stromal vascular fraction, which contains macrophages, T cells, and adipose progenitor cells. Visceral fat contains proportionally more stromal cells than subcutaneous fat, and during obesity, monocyte recruitment into visceral depots accelerates through the CCL2/CCR2 axis.

The consequence is depot-specific macrophage polarization. In lean states, adipose tissue macrophages are predominantly M2-polarized (anti-inflammatory). With visceral expansion, the ratio shifts toward M1-polarized (pro-inflammatory) macrophages that produce TNF-α, IL-6, and IL-1β. These macrophages cluster around dying hypertrophied adipocytes in characteristic crown-like structures, the histological signature of inflamed visceral fat. Subcutaneous fat maintains a more M2-dominant profile for longer, partly explaining its more benign inflammatory character.

The 11β-HSD1 cortisol amplifier

One more layer worth knowing about. Visceral fat expresses higher activity of an enzyme called 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive cortisone into active cortisol locally inside the tissue. This means visceral fat amplifies its own glucocorticoid signaling independent of your circulating cortisol levels. Higher local cortisol drives further fat redistribution from peripheral to central depots and impairs insulin signaling through JNK activation.

The story has a complication worth acknowledging. While most studies find higher 11β-HSD1 activity in visceral fat, a 2012 study in obese women actually showed reduced visceral 11β-HSD1 activity compared to lean controls, a finding not seen in obese men. The enzyme appears to be regulated by sex hormones, and its net effect varies by sex, age, and obesity class. The general direction holds, but the magnitude is not uniform.

How to Measure Visceral Fat: What Works, What Doesn't

If visceral fat matters more than total body fat, you need a way to measure it. Important metrics for assessing visceral fat and related health risks include body fat percentage, waist to hip ratio, and waist size, as these provide more insight into fat distribution than weight alone. The methods available range from research-grade gold standards to consumer scales that are essentially making educated guesses. Knowing the difference will save you from drawing the wrong conclusions about your body.

Gold standard: CT and MRI

Computed tomography and magnetic resonance imaging remain the most accurate methods for quantifying visceral fat. A single axial slice at the L4-L5 level provides visceral fat area in square centimeters, and multi-slice volumetric analysis allows total visceral fat volume measurement. Both methods can also distinguish liver fat, pancreatic fat, and other ectopic depots. CT is faster and cheaper but uses ionizing radiation; MRI avoids radiation but costs more and is less accessible. Both are research-grade tools rather than routine clinical screening for most patients.

DEXA: useful, with caveats

DEXA (dual-energy X-ray absorptiometry) estimates visceral fat using algorithms that analyze attenuation differences in the abdominal region. A large 2026 UK Biobank analysis (n=18,622) found DEXA-derived android fat had ICC values of 0.73 to 0.94 against MRI-determined visceral fat, the strongest correlation among non-MRI methods. DEXA also provides body composition data, including body fat percentage, far beyond visceral fat, which makes it useful clinically.

The limitations: DEXA cannot anatomically distinguish deep subcutaneous fat from visceral fat (it can only estimate based on regional attenuation patterns), tends to overestimate visceral fat compared to MRI due to subcutaneous interference, and shows proportional bias in some populations including children, older men, and post-bariatric patients.

BIA scales: mostly marketing

Bioelectrical impedance analysis (the technology in most "smart scales" and gym body composition machines) performs poorly for visceral fat estimation specifically. A 2021 BMJ Open study comparing BIA against CT showed correlation coefficients of 0.387 to 0.636, with sensitivity of only 65% in women and 76% in men using manufacturer-recommended thresholds.

The mechanistic reason is straightforward. BIA estimates body water content via electrical resistance and applies regression equations to estimate fat mass. The relationship between tissue resistance and the visceral compartment specifically is an empirical estimate stacked on multiple assumption layers, none of which directly measure intra-abdominal fat. Your scale's "visceral fat level" reading is a directional indicator at best. Treat it as a trend line, not a diagnostic number.

The most underrated tool: a tape measure

For most people, the most accessible and clinically useful proxy for visceral fat risk is the waist-to-height ratio (WHtR). Alongside WHtR, both waist size and waist-to-hip ratio are commonly used to assess abdominal obesity and visceral fat risk, as they provide simple, accessible indicators of excess visceral fat and associated health risks. The same 2026 UK Biobank analysis found waist circumference had ICC values of 0.73 to 0.77 with MRI-determined visceral fat, making it the most appropriate practical surrogate for routine assessment.

WHtR consistently outperforms both BMI and waist circumference alone. A 2025 Lancet Regional Health Americas study (n=2,721 adults, 5+ years of follow-up) found that after adjusting for classical cardiovascular risk factors, only WHtR retained independent predictive value for future cardiovascular disease. A 2025 NHANES analysis of more than 19,000 adults found high WHtR was associated with 50 to 82% higher likelihood of elevated blood pressure and hypertension. The threshold of 0.5 (your waist should be less than half your height) is a robust cutoff for elevated cardiometabolic risk, with 0.59 specifically proposed as a threshold for visceral obesity.

A flexible tape measure and a basic division calculation outperform most consumer body composition scales for tracking visceral fat risk. Cost: zero. Sensitivity to change: better than scale weight.

✦ Practical Tool: How to Measure Your Waist-to-Height Ratio

Step 1. Stand relaxed, exhale normally. Wrap a flexible tape measure around your bare midsection at the level of your belly button (approximately the narrowest point of your torso, which is also where the L4-L5 reference line in imaging studies sits).

Step 2. Record the measurement in inches. Do not pull the tape tight. It should be snug enough not to sag but not compressing the skin.

Step 3. Divide your waist measurement by your height in the same units. A 36-inch waist on a 70-inch (5'10") frame: 36 ÷ 70 = 0.514.

Step 4. Interpret:

• Below 0.5: lower cardiometabolic risk

• 0.5 to 0.58: elevated risk; intervention warranted

• 0.59 and above: high probability of visceral obesity; address actively

Track this every 4 weeks during a fat-loss phase. WHtR is more sensitive to visceral fat changes than scale weight, and it does not require any equipment.

What the Numbers Mean: Risk Stratification

Once you have a measurement, what does it actually predict? The hazard ratio data on visceral fat across cardiometabolic outcomes is some of the strongest in obesity research, and worth knowing in concrete terms. Too much fat, especially excess visceral fat and abdominal obesity, is associated with a higher risk of health problems, including heart disease, high blood pressure, metabolic syndrome, and other associated health risks.

Type 2 diabetes risk. Visceral adiposity independently predicts insulin resistance and T2D risk beyond BMI and total fat mass. Adipocyte morphology studies show that participants with insulin resistance have larger visceral adipocytes and lower adiponectin-to-leptin ratios independent of total adiposity. Too much visceral fat is a key driver of metabolic syndrome, which further increases the risk of developing type 2 diabetes and other health problems.

Cardiovascular disease. A 2025 cross-sectional study using CT to quantify visceral fat in T2DM patients found visceral fat area was independently associated with CVD risk (OR 1.43, 95% CI 1.12-1.65). Each 0.5-unit increase in the Visceral Adiposity Index is associated with a 14.4% rise in CVD risk and 19.0% increase in cardiovascular death, in a roughly linear dose-response pattern. Excess visceral fat and abdominal obesity are strongly linked to higher risk of heart disease, high blood pressure, and other associated health risks.

All-cause mortality. The Metabolic Score for Visceral Fat (METS-VF), a validated proxy combining BMI, waist-hip ratio, age, sex, and metabolic markers, shows clear dose-dependent mortality associations. In US adults with diabetes or prediabetes followed for a median of 97 months, the highest METS-VF quartile had an adjusted hazard ratio of 2.857 for all-cause mortality and 3.290 for cardiovascular mortality compared to the lowest quartile. Belly fat raises the risk of multiple health problems, including cardiovascular disease, metabolic syndrome, and other serious health risks.

Liver disease. Visceral fat drives MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) through the portal mechanism described above. Individuals with normal-weight MASLD, who tend to have disproportionately high visceral fat relative to total fat mass, often show worse cardiometabolic profiles than obese individuals without MASLD. NAFLD itself carries a hazard ratio of 1.26 for all-cause mortality, 1.33 for cardiac mortality, and 1.55 for cancer mortality in community follow-up data.

What Actually Reduces Visceral Fat

This is where the evidence gets practical, and where most popular advice is not actually wrong but is missing the most interesting finding in the recent literature. To lose weight and achieve less visceral fat, a combination of exercise and dietary changes is recommended. Aerobic activities like brisk walking and high intensity interval training (HIIT) are effective for reducing visceral fat, especially when performed consistently. Resistance training is also important, as it helps preserve muscle mass, including abdominal muscles and belly muscles, during weight loss, supporting a healthier body composition.

Dietary strategies should focus on a balanced diet that includes lean protein sources such as chicken, fish, eggs, beans, and low-fat dairy, while reducing intake of processed foods and saturated fat. These changes not only help lose visceral fat but also support overall metabolic health.

Exercise has a dose-response effect on visceral fat. Caloric restriction does not.

The single most important paper here is the Recchia et al. 2023 systematic review and meta-analysis published in the British Journal of Sports Medicine. The authors pooled 40 randomized controlled trials with 2,190 participants, comparing exercise and caloric restriction for their effects on visceral fat measured by imaging.

Both interventions reduced visceral fat: exercise with an effect size of -0.28, caloric restriction with -0.53, both highly statistically significant. So far, no surprise. The interesting finding came when the authors analyzed dose-response. Only exercise showed a dose-response relationship: visceral fat decreased by an additional -0.15 effect size for every 1,000 kcal per week of additional exercise deficit. Caloric restriction showed no dose-dependent effect (p=0.64). When the two interventions were directly compared at matched energy deficits, exercise had the superior dose-response on visceral fat (ES -0.18, p=0.012).

Even more striking: in studies where exercise was performed without weight loss (energy intake increased to match expenditure), exercise still produced approximately a 6.1% reduction in visceral fat, while equivalent caloric restriction without exercise produced essentially no change in visceral fat in the absence of weight loss.

Recchia et al., 2023, British Journal of Sports Medicine — meta-analysis of 40 randomized controlled trials, n=2,190. Exercise without weight loss still reduced visceral fat by approximately 6.1%. Caloric restriction without exercise did not.

Both brisk walking (a moderate-intensity aerobic activity) and high intensity interval training (HIIT) have been shown to be effective for reducing visceral fat. Brisk walking is accessible and sustainable for most people, while HIIT can deliver superior results in less time and is often combined with resistance training for optimal fat reduction.

The mechanism is consistent with everything covered above. Exercise engages the β3-adrenergic catecholamine pathway that visceral adipocytes are especially responsive to, and it lowers circulating insulin levels, which removes the anti-lipolytic brake preferentially in the less insulin-sensitive visceral depot. Caloric restriction without exercise reduces fat broadly but does not preferentially target the visceral compartment.

Practical implication: if your goal is specifically reducing visceral fat (not just weight loss), exercise is non-negotiable, not optional. The data does not support diet-only approaches as equivalent for this specific outcome.

Aerobic vs resistance training

For visceral fat specifically, aerobic exercise drives the larger reduction, likely through the catecholamine-stimulated lipolysis pathway. A 2025 Frontiers in Nutrition meta-analysis found aerobic exercise more effective than resistance training and combined approaches for absolute body fat reduction, with efficacy increasing at higher intensities.

Resistance training plays a different role: under caloric restriction, it preserves muscle mass and strengthens abdominal muscles and belly muscles, which improves body composition (fat percentage) and supports long-term metabolic rate. A 2026 review identified resistance training as the modality most associated with fat-mass reduction in men while increasing fat-free mass.

The optimal approach for someone trying to reduce visceral fat is generally aerobic work for direct visceral fat mobilization plus resistance training for muscle preservation and metabolic floor. They are complementary, not interchangeable.

GLP-1 receptor agonists: depot-specific effects

GLP-1 and dual GIP/GLP-1 agonists (semaglutide and tirzepatide) deserve a serious mention because their effects on body composition are not symmetric across depots. In the SURMOUNT-1 DXA substudy of tirzepatide, visceral fat mass decreased by approximately 40% versus 7% with placebo, an estimated treatment difference of 33 percentage points. The SURPASS-3 MRI study found tirzepatide reduced visceral fat z-scores by 0.18 SD and liver fat z-scores by 0.54 SD, while subcutaneous fat actually increased slightly (+0.11 SD).

That last detail is mechanistically important. Tirzepatide does not just reduce fat globally. It appears to redistribute fat from visceral and hepatic depots toward subcutaneous storage, shifting the body toward a more metabolically favorable distribution independent of total weight loss. Semaglutide shows similar but somewhat less pronounced depot-specific effects, with tirzepatide demonstrating superior visceral fat reduction in head-to-head comparisons over comparable durations.

Mechanistically, GLP-1 agonists reduce visceral fat through three converging effects: appetite suppression and resulting caloric deficit (with preferential visceral mobilization), direct GLP-1 receptor signaling in adipocytes promoting lipolysis and adiponectin secretion, and browning-associated gene upregulation in subcutaneous fat that increases thermogenic capacity.

Where the Simple VAT-vs-SAT Story Breaks Down

The mechanism story above is largely correct but increasingly recognized as incomplete. Body fat distribution and body shape play important roles in how visceral fat accumulation occurs and the associated health risks. Three findings from the past several years complicate the simple binary, and they matter for anyone trying to understand body composition past the headline level.

Deep subcutaneous abdominal fat: a visceral mimic

The fascia of Scarpa divides abdominal subcutaneous fat into a superficial layer and a deep layer. A 2014 Diabetes Care study first demonstrated that deep subcutaneous abdominal tissue (dSAT), not the superficial layer, was a strong independent predictor of HOMA-IR, hepatic insulin resistance, and Framingham cardiovascular risk score in men.

Subsequent work has shown that dSAT expresses higher levels of pro-inflammatory, lipogenic, and lipolytic genes than superficial SAT, contains a higher proportion of small adipocytes, and shows fatty acid composition closer to visceral fat than to typical subcutaneous fat. A 2025 American Journal of Physiology Cell Physiology study using bulk and single-cell RNA sequencing confirmed that dSAT is enriched for inflammatory and tissue remodeling pathways, qualifying it as a pro-inflammatory and remodeling-prone tissue distinct from conventional SAT.

Clinical implication: waist circumference does not distinguish dSAT from superficial SAT. Two people with identical waist measurements may have very different metabolic risk depending on the proportion of their abdominal subcutaneous fat that is dSAT versus superficial. This is one reason why imaging-based assessment is more accurate than tape-based assessment for sophisticated risk stratification.

Subcutaneous fat as a metabolic buffer (the expandability hypothesis)

A growing body of evidence frames the question differently. The most important determinant of whether obesity causes metabolic disease may not be how much visceral fat you have, but how much your subcutaneous fat can expand to absorb caloric surplus before lipid spillover into visceral and ectopic depots begins.

This is the expandability hypothesis. When subcutaneous fat reaches its storage capacity (which is genetically determined, sex-dependent, and modifiable through training), excess lipid gets shunted into visceral fat, intrahepatic fat, intramyocellular fat, pericardial fat, and pancreatic fat. Cardiometabolic disease is the consequence of ectopic deposition, not adiposity per se.

Supporting evidence: SAT transplantation in mice (not VAT transplantation) produces beneficial metabolic effects. The Framingham Heart Study showed that in the highest VAT tertile, higher SAT was actually associated with lower triglycerides in men, an apparent buffering effect. And endurance training over 2 years in obese individuals improves SAT capillary density, reduces extracellular matrix fibrosis, and improves SAT's storage capacity, which protects against ectopic fat accumulation.

Normal-weight visceral obesity

You can have a normal BMI and still have a metabolically problematic body composition. This phenotype is sometimes called thin outside, fat inside (TOFI), or "normal-weight obesity." Individuals can fall within a healthy weight or healthy weight range based on BMI, yet still carry unhealthy levels of visceral fat. The 2025 Lancet study cited above found that individuals with BMI under 30 but WHtR over 0.5 face elevated coronary artery calcification risk, even in the absence of other cardiovascular risk factors.

This phenotype is particularly common in Asian populations, who tend to develop visceral adiposity at lower BMI thresholds, which is why the World Health Organization recommends lower BMI cutoffs for obesity classification in Asian cohorts. It also occurs in sedentary individuals of any ethnicity who lose subcutaneous muscle and gain visceral fat without changing scale weight, meaning it is possible to gain weight in the form of visceral fat without a significant increase in overall body weight, the classic "skinny fat" phenotype.

The practical implication: BMI alone misses this group entirely. WHtR catches them. So does any imaging-based body composition assessment. The lesson is not that BMI is useless. It is that BMI is necessary but not sufficient, and central adiposity assessment should be part of any serious metabolic evaluation.

Your Visceral Fat Reduction Timeline

Frequently Asked Questions

What is the difference between visceral fat and subcutaneous fat?

Visceral fat surrounds the organs in your abdominal cavity (primarily omental and mesenteric fat). Subcutaneous fat sits directly under your skin. When comparing subcutaneous versus visceral fat, it's important to note that visceral fat is more metabolically active and has a greater impact on health risks, while subcutaneous fat is generally less harmful. The two depots differ in cell biology, hormone secretion, sympathetic innervation, and most critically, venous drainage. Visceral fat drains into the portal vein, exposing the liver to undiluted fatty acids and inflammatory cytokines. Subcutaneous fat drains into systemic circulation and is diluted before reaching any organ. This anatomical difference explains why visceral fat is more strongly linked to cardiometabolic disease than subcutaneous fat at equivalent total body fat.

What is a normal visceral fat level?

The most accessible practical threshold is waist-to-height ratio: below 0.5 indicates lower risk, above 0.5 indicates elevated risk, and 0.59 or higher indicates a high probability of visceral obesity. On DEXA scans, visceral adipose tissue area below approximately 100 cm² is generally considered low risk, 100 to 160 cm² is moderate, and above 160 cm² is high. BIA scale "visceral fat level" readings are device-specific and should be treated as trend lines rather than absolute thresholds.

What causes visceral fat?

The main drivers are caloric surplus combined with hyperinsulinemia, sedentary behavior, poor sleep, chronic psychological stress (which elevates cortisol and 11β-HSD1 activity in fat tissue), low protein intake, and high refined carbohydrate intake. Genetic factors set baseline susceptibility, with men, postmenopausal women, and individuals of Asian or South Asian descent showing higher tendency for visceral accumulation. Aging shifts fat distribution toward central depots independently of total fat mass, partly through declining sex hormone levels and reduced subcutaneous fat expandability.

How do I lose visceral fat specifically?

Exercise is the most evidence-supported intervention specifically for visceral fat reduction, with a dose-response relationship that caloric restriction alone does not show. Aim for 150 to 250 minutes per week of moderate-intensity aerobic exercise plus 2 to 3 resistance training sessions for muscle preservation. Combine with a moderate caloric deficit and a diet pattern that addresses hyperinsulinemia (reduced refined carbohydrate, adequate protein, fiber from whole foods). GLP-1 receptor agonists show preferential visceral fat reduction in clinical trials and may be appropriate for individuals with obesity or T2D under medical supervision. Sleep optimization and stress management matter more than typically appreciated, given the role of cortisol and 11β-HSD1 in driving central adiposity.

Can you have visceral fat without being overweight?

Yes. The phenotype is sometimes called normal-weight obesity or "thin outside, fat inside" (TOFI). Individuals can have high visceral fat even if they are at a healthy weight according to BMI. For example, people with BMI below 30 but a waist-to-height ratio above 0.5 can carry disproportionately high visceral fat and face elevated cardiovascular and diabetes risk despite normal scale weight. This is why central adiposity assessment (waist measurement, WHtR, or imaging) should accompany any serious metabolic evaluation rather than relying on BMI or healthy weight status alone.

Is a DEXA scan worth it for measuring visceral fat?

For most people interested in serious body composition tracking, yes. DEXA provides reasonably accurate visceral fat estimates (with caveats about overestimation versus MRI), good total body fat and lean mass measurement, and regional distribution data, including body fat percentage, which is a more precise indicator of health risk than BMI alone. For research-grade visceral fat measurement, MRI remains the gold standard but is generally not accessible outside research or specialty contexts. For ongoing tracking, waist-to-height ratio is sufficient for most clinical purposes and costs nothing.

Why does visceral fat affect the liver more than other organs?

Anatomy. Visceral fat from omental and mesenteric depots drains via the portal vein directly into the liver before any dilution in systemic circulation. Visceral fat makes and releases substances, including fatty acids, inflammatory cytokines (IL-6, TNF-α, MCP-1), and hormone precursors, that directly affect the liver. This delivers these compounds at concentrations the liver does not encounter from any other source. The liver responds with increased gluconeogenesis, lipid accumulation, insulin receptor downregulation, and eventually steatosis. No other tissue has this anatomical exposure pattern, which is why visceral fat is uniquely associated with hepatic insulin resistance and MASLD/NAFLD.

Free Discovery CallGet The BookMore Metabolic ArticlesYouTube Channel

About Dr. Michael Fitzmaurice, M.D.

Peripheral Nerve Surgeon & Metabolic Health Educator

Dr. Michael Fitzmaurice is a fellowship-trained peripheral nerve surgeon with a background in nerve physiology, metabolic health, and applied exercise physiology. Through years of surgical practice, he has observed the close relationship between metabolic health, cellular energy production, and nervous system function. His work focuses on how physical activity, recovery biology, and nutrition-informed strategies relate to long-term nerve and metabolic health.

He oversees Dr. Fitz Nutrition, an education-first initiative translating evidence-informed research into thoughtfully designed formulations for nerve and metabolic health, and believes that patients who understand the science make better decisions about their care.